Sartorius Aktiengesellschaft (ETR:SRT) Shares Down 0.6% - Should You Sell?

Key Points

• Shares fell 0.6% to €179.00 on Thursday, trading as low as €178.20 on volume of 2,534 shares versus a prior close of €180.00.
• Valuation and technicals: Market capitalization is $13.91 billion with a high P/E of 90.04 and PEG of 2.28; the 50‑day MA (€176.70) sits below the 200‑day MA (€184.18).
• Balance-sheet risk despite biotech focus: Sartorius provides bioprocess and lab products but carries very high leverage (debt/equity 164.56) and weak liquidity (quick ratio 0.36, current ratio 0.90).

Sartorius Aktiengesellschaft (ETR:SRT - )'s stock price fell 0.6% on Thursday . The stock traded as low as €178.20 and last traded at €179.00. 2,534 shares were traded during mid-day trading, The stock had previously closed at €180.00.

Sartorius Aktiengesellschaft Price Performance

The company has a market capitalization of $13.91 billion, a price-to-earnings ratio of 90.04, a price-to-earnings-growth ratio of 2.28 and a beta of 1.51. The company has a 50-day moving average price of €176.70 and a 200-day moving average price of €184.18. The company has a debt-to-equity ratio of 164.56, a quick ratio of 0.36 and a current ratio of 0.90.

Sartorius Aktiengesellschaft Company Profile

Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services in the United States and internationally. The company offers multi-parallel, benchtop, single-use, stainless steel, cell culture, rocking motion, and microbial bioreactors, and software apps for bioreactors and cell culture shake flask; fermenters; cell culture media products; cellcelector flex, incubator flowbox, nanowell arrays, and capillaries and tips; fluid management products; microbiology products; and Ultrafiltration membrane filters, glass and quartz microfiber filters, clarification, syringeless and in-line filters, lab chromatography, and filters and blotting papers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.